Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-12-28
2004-07-06
Chang, Ceila (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S224000
Reexamination Certificate
active
06759420
ABSTRACT:
Under the provisions of Section 119 of 35 U.S.C., Applicants hereby claim the benefit of the filing date of European Patent Application 99100001.9, filed Jan. 2, 1999, and European Patent Application 99119538.9, filed Oct. 1, 1999, which applications are hereby incorporated by specific reference.
The present invention relates to new compounds for the inhibition of blood clotting proteins and the inhibition of factor Xa activity, and more particularly, to arylalkanoyl derivatives of the formula (I):
wherein R(1), R(2), R(3), R(4), R(5), R(6a) and R(6b) are defined as indicated below. The invention also relates to processes for the preparation of the compounds of formula (
1
), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula (I) in the treatment and prophylaxis of diseases which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (I) in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (I) together with pharmeceutically acceptable carrier substances and auxiliary substances.
The ability to form blood clots is vital to survival. In certain disease states, however, the formation of blood clots within the circulatory system is itself a source of morbidity. It is nevertheless not desirable in such disease states to completely inhibit the clotting system because life threatening hemorrhage would ensue. In order to reduce the instances of the intravascular formation of blood clots those skilled in the art have endeavoured to develop an effective inhibitor of factor Xa, or prothrombinase, the enzyme which is incorporated into the prothrombinase complex where it serves to activate thrombin during clot formation. Appropriate concentrations of such an inhibitor would increase the level of prothrombinase forming agents required to initiate clotting, but would not unduly prolong the clotting proces once a threshold concentration of thrombin had been obtained.
Blood coagulation is a complex process involving a progressively amplified series of enzyme activation reactions in which plasma zymogens are sequentially activated by limited proteolysis. Mechanically, the blood coagulation cascade has been divided into intrinsic and extrinsic pathways, which coverage at the activation of factor X; subsequent generation of the thrombin proceeds through a single common pathway (see Scheme 1 below):
The present evidence suggests that the intrinsic pathway plays an important role in the maintenance and growth of fibrin formation, while the extrinsic pathway is critical in the initiation phase of blood coagulation. It is generally accepted that blood coagulation is physically initiated upon formation of a tissue factor (“TF”)/factor Vlla complex. Once formed, this complex rapidly initiates coagulation by activating factors IX and X. The newly generated activated factor X, i.e., factor Xa, then forms a one-to-one complex with factor Va and phospholipids to form a prothrombinase complex, which is responsible for converting souble fibrinogen to insoluble fibrin via the activation of thrombin from its precursor prothrombin. As time progresses, the activity of the factor Vlla/TF complex (extrinsic pathyway) is suppressed by a Kunitz-type protease inhibitor protein TFPI, which, when complexed to factor Xa, can directly inhibit the proteolytic activity of factor Vlla/tissue factor, In order to maintain the coagulation process in the presence of an inhibited extrinsic system, additional factor Xa is produced via the thrombin-mediated activity of the intrinsic pathway. Thus, thrombin plays a dual autocatalytic role: mediateing its own production and converting fibrinogen to fibrin.
The autocatalytic nature of thrombin generation is an important safeguard against uncontrolled bleeding and it ensures that, once a given threshold level of prothrombinase is present, blood coagulation will proceed to completion, thereby effecting, for example, an end of the hemorrhage. Thus, it is most desirable to develop agents that inhibit coagulation without directly inhibiting thrombin. However, despite the long standing recognition of the desirability of such an inhibitor, there is at present no effective specific Xa inhibitor in clinical use.
In many clinical applications there is a great need for the prevention of intravascular blood clots or for anti-coagulant therapy. The currently available drugs are not satisfactory in many specific clinical applications. For example, nearly 50% of patients who have undergone a total hip replacement develop deep vein thrombosis (“DVT”). The currently approved therapies are fixed dose low molecular weight heparin (“LMWH”) and variable dose heparin. Even with these drug regimes 10% to 20% of patients develop DVT and 5% to 10% develop bleeding complications.
Another clinical situation for which better anticoagulants are needed concerns subjects undergoing transluminal coronary angioplasty and subjects at risk for myocardial infarction or angina.
The most widely used blood-clotting inhibitors are heparin and the related sulfated polysaccharides: LMWH and heparin sulfate. These molecules exert their anti-clotting effects by promoting the binding of a natural regulator of the clotting process, anti-thrombin III, to thrombin and to factor Xa. The inhibitory acitivity of heparin primarily is directed toward thrombin, which is inactivated approximately 100 times faster than factor Xa. Although relative to heparin, heparin sulfate and LMWH are somewhat more potent inhibitors of Xa than of thrombin, the differences in vitro are modest (3-30 fold) and effects in vivo can be inconsequential. Hirudin and hirulog are two additional thrombin-specific anticoagulants that have been tested in clinical trials. However, these anticoagulants, which inhibit thrombin, are also associated with bleeding complications.
Preclinical studies in baboons and dogs have shown that specific inhibitors of factor Xa prevent clot formation without producing the bleeding side effects observed with direct thrombin inhibitors.
Several specific inhibitors of factor Xa have been reported. Both synthetic and protein inhibitors of factor Xa have been identified, and these include, for example, antistasin (“ATS”) and tick anticoagulant peptide (“TAP”). ATS, which is isolated from the leech,
Haementerin officinalis
, contains 119 amino acids and has a Ki for factor Xa of 0.05 nM. TAP, which is isolated from the tick,
Ornithodoros moubata
, contains 60 amino acids and has a Ki for factor Xa of about 0.5 nM.
The effectiveness of recombinantly-produced ATS and TAP have been investigated in a number of animals model systems. Both inhibitors decrease bleeding time compared to other anticoagulants, and prevent clotting in a thromboplastin-induced, ligated jugular vein model of deep vein thrombosis. The results achieved in this model correlate with results obtained using the current drug of choice, heparin.
Subcutaneous ATS also was found to be an effective treatment in a thromboplastin-induced model of disseminated intravascular coagulation (“DIC”). TAP effectively prevents “high-shear” arterial thrombosis and “reduced flow” caused by the surgical placement of a polyester (“DACRON”) graft at levels that produced a clinically acceptable prolongation of the activated partial thromboplastin time (“aPTT”), i.e., less than about two fold prolongation. By comparison, standard heparin, even at doses causing a five fold increase in the aPTT, did not prevent thrombosis and reduced flow within the graft. The aPTT is a clinical assay of coagulation which is particularly sensitive to thrombin inhibitors.
ATS and TAP have not been developed clinically. One major disadvantage of these two inhibitors is that administration of the required repeated doses causes the
Al-Obeidi Fahad A.
Defossa Elisabeth
Heinelt Uwe
Klingler Otmar
Matter Hans
Aventis Pharma Deutschland GmbH
Chang Ceila
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Robinson Binta
LandOfFree
Arylalkanoyl derivatives, processes for their preparation,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylalkanoyl derivatives, processes for their preparation,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkanoyl derivatives, processes for their preparation,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3243095